PDCD1 and neoplasm: Coincidently, the increased presence of non‐classical monocytes, along with their enhanced Type 1 interferon response, which inhibits angiogenesis and promotes an anti‐tumour immune response in the TME, may contribute to a better response to PD‐1 inhibitor + TKI treatment in patients without myosteatosis [37].